Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.

被引：0

作者：

Hamai, Kosuke

Masuda, Takeshi

Fujitaka, Kazunori

Suzuki, Tomoko

Matsumoto, Naoko

Matsumura, Mirai

Isoyama, Shoko

Ueno, Sayaka

Mito, Mineyo

Yamaguchi, Kakuhiro

Sakamoto, Shinjiro

Kawano, Reo

Masuda, Ken

Nishino, Ryohei

Ishikawa, Nobuhisa

Yamasaki, Masahiro

Hattori, Noboru

机构：

[1] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan

[2] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan

[3] JA Onomichi Gen Hosp, Dept Resp Internal Med, Onomichi, Japan

[4] Hiroshima Red Cross Hosp & Atom Bomb Survivors Ho, Dept Resp Internal Med, Hiroshima, Japan

[5] Kure Med Ctr, Dept Resp Internal Med, Hiroshima, Japan

[6] Hiroshima Univ Hosp, Hiroshima, Japan

[7] Hiroshima City Hiroshima Citizens Hosp, Dept Resp Internal Med, Hiroshima, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21156

引用

页数：1

共 50 条

[21] Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression [J].

Ikezawa, Yasuyuki ;

Mizugaki, Hidenori ;

Morita, Ryo ;

Tateishi, Kazunari ;

Yokoo, Keiki ;

Sumi, Toshiyuki ;

Kikuchi, Hajime ;

Kitamura, Yasuo ;

Nakamura, Atsushi ;

Kobayashi, Maki ;

Aso, Mari ;

Kimura, Nozomu ;

Yoshiike, Fumiaki ;

Furuta, Megumi ;

Tanaka, Hisashi ;

Sekikawa, Motoki ;

Hachiya, Tsutomu ;

Nakamura, Keiichi ;

Shimokawa, Mototsugu ;

Oizumi, Satoshi .

CANCER SCIENCE, 2022, 113 (06) :2109-2117

[22] Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer [J].

Fujii, Hironori ;

Araki, Ayumu ;

Iihara, Hirotoshi ;

Kaito, Daizo ;

Hirose, Chiemi ;

Kinomura, Motohiko ;

Yamazaki, Mizuki ;

Endo, Junki ;

Inui, Toshiya ;

Yanase, Komei ;

Sasaki, Yuka ;

Gomyo, Takenobu ;

Sakai, Chizuru ;

Kawae, Daisuke ;

Kitamura, Yu ;

Fukui, Masachika ;

Kobayashi, Ryo ;

Ohno, Yasushi ;

Suzuki, Akio .

MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (04)

[23] First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer [J].

Travert, Camille ;

Tomasini, Pascale ;

Jeanson, Arnaud ;

Greillier, Laurent ;

Barlesi, Fabrice .

TRANSLATIONAL CANCER RESEARCH, 2019, 8 (07) :2514-2516

[24] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly [J].

Losanno, Tania ;

Gridelli, Cesare .

CURRENT ONCOLOGY REPORTS, 2021, 23 (10)

[25] Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer [J].

Masuda, Takeshi ;

Fujitaka, Kazunori ;

Ishikawa, Nobuhisa ;

Nakano, Kikuo ;

Yamasaki, Masahiro ;

Kitaguchi, Souichi ;

Masuda, Ken ;

Yamaguchi, Kakuhiro ;

Sakamoto, Shinjiro ;

Horimasu, Yasushi ;

Kawase, Shigeo ;

Miyamoto, Shintaro ;

Nakashima, Taku ;

Iwamoto, Hiroshi ;

Shiota, Naoki ;

Senoo, Tadashi ;

Awaya, Yoshikazu ;

Kondo, Tomohiro ;

Yoshida, Takashi ;

Hamada, Hironobu ;

Murakami, Isao ;

Hattori, Noboru .

JOURNAL OF THORACIC DISEASE, 2020, 12 (03) :1079-1084

[26] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly [J].

Tania Losanno ;

Cesare Gridelli .

Current Oncology Reports, 2021, 23

[27] Pembrolizumab mono versus Pembrolizumab plus Chemotherapy as first-line Palliative Therapy for PD-L1-high positive Non-small Cell Lung Cancer: a Two-center Study [J].

Olive, E. ;

Frost, N. ;

Grohe, C. .

PNEUMOLOGIE, 2022, 76 :S93-S93

[28] Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer [J].

Shah, Mohsin ;

Marmarelis, Melina E. ;

Mamtani, Ronac ;

Hennessy, Sean .

CLINICAL LUNG CANCER, 2022, 23 (08) :731-736

[29] Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China [J].

Liao, Weiting ;

Huang, Jiaxing ;

Hutton, David ;

Li, Qiu .

JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) :344-349

[30] Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients [J].

Barrichello, Adriana P. C. ;

Elkrief, Arielle ;

Ricciuti, Biagio ;

Ganta, Teja ;

Marron, Thomas U. ;

Wang, Xinan ;

Lotter, William ;

Lindsay, James ;

Santo, Valentina ;

Cortellini, Alessio ;

Sharma, Bijaya ;

Felt, Kristen ;

Pfaff, Kathleen ;

Lamberti, Giuseppe ;

Pecci, Federica ;

Di Federico, Alessandro ;

Makarem, Maisam ;

Gandhi, Malini M. ;

Nguyen, Tom ;

Haradon, Danielle ;

Vaz, Victor R. ;

Johnson, Bruce E. ;

Debnath, Neha ;

Wang, Yinghong ;

Kuang, Andrew G. ;

Saeed, Anwaar ;

Radford, Maluki ;

Lovly, Christine M. ;

Nebhan, Caroline A. ;

Pinato, David J. ;

Rodig, Scott J. ;

Schoenfeld, Adam J. ;

Awad, Mark M. ;

Alessi, Joao, V ;

Naqash, Abdul Rafeh .

CLINICAL LUNG CANCER, 2025, 26 (04)

← 1 2 3 4 5 →